ResearcherCzech Academy of Sciences, Institute of BiotechnologyNo recent work listed
Jiřı́ Neužil
Matched on ORCID iD 0000-0002-2478-2460; OpenAlex author ID A5060128303. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers
Papers 5
- SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. Last author DOI 10.1038/s41388-021-01726-4↗
- Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer. Last author DOI 10.18632/oncotarget.27976↗
- TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor. Co-author DOI 10.1016/j.bbamcr.2017.12.006↗
- Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-15-1021↗
- Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. Co-author DOI 10.1186/s12885-016-2343-9↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Štěpána Boukalová · 4 shared papers, 2016–2021 · strength 0.46
- Paper Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer. DOI 10.18632/oncotarget.27976↗
- Paper SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. DOI 10.1038/s41388-021-01726-4↗
- Paper Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. DOI 10.1186/s12885-016-2343-9↗
- Zuzana Ezrova · 3 shared papers, 2016–2021 · strength 0.40
- Paper Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer. DOI 10.18632/oncotarget.27976↗
- Paper SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. DOI 10.1038/s41388-021-01726-4↗
- Paper Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer. DOI 10.1158/1535-7163.mct-15-1021↗
- Zuzana Nahácka · 2 shared papers, 2018–2021 · strength 0.21
- Paper SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. DOI 10.1038/s41388-021-01726-4↗
- Paper TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/D… DOI 10.1016/j.bbamcr.2017.12.006↗
- Ladislav Anděra · 1 shared paper, 2018 · strength 0.09
- R Gürlich · 1 shared paper, 2016 · strength 0.06
- Tomáš Ruml · 1 shared paper, 2016 · strength 0.06
- Katerina Hadrava Vanova · 1 shared paper, 2016 · strength 0.06
- Helena Gbelcová · 1 shared paper, 2016 · strength 0.06
- Libor Vı́tek · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.